Abstract
In this double-blind, randomised, placebo-controlled cross-over study the respiratory effects of Mr 2264 Cl2 × 5 mg IV, a new partial opiate receptor agonist, were investigated and compared with the respiratory effects of morphine 2 × 10 mg IV and placebo. As primary end-points, the slope of the rebreathing curve (dV'/dPCO2ET) and V55 (ventilation at PCO2ET=55 mm Hg) were determined by Read's rebreathing method. The incidence of adverse events was also documented and compared.
The respiratory depression after the intravenous administration of 5 mg and 10 mg Mr 2264 Cl was comparable to the decreased sensitivity of the respiratory centre after the 20 mg morphine IV. In contrast to morphine, a ceiling effect of Mr 2264 Cl was found. The tolerability of Mr 2264 Cl was comparable to that of morphine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ensinger HA, Stockhaus K, Merz H (1984) Methods and findings. Exp Clin Pharmacol 6: 649–652
Jacobson AE (1985) Problems of drug dependence. Proceedings of the 47th Annual Scientific Meeting, National Institute on Drug Abuse. Res Monogr Series 67: 385–398
Read DJC (1966) A clinical method for assessing the ventilatory response to carbon dioxide. Austr Ann Med 16: 20–32
Read DJC, Leigh J (1967) Blood-brain tissue PCO2 relationships and ventilation during rebreathing. J Appl Physiol 23: 53–70
Behne M (1991) Der Einfluß von Flumazenil auf eine durch Fentanyl verursachte Atemdepression. Anaesthesist 40: 271–275
Jacobson AE (1982) Problems of drug dependence. Proceedings of the 44th Annual Scientific Meeting, National Institute on Drug Abuse. Res Monogr Series 43: 389–398
Romagnoli A, Keats AS (1980) Ceiling effect for respiratory depression by nalbuphine. Clin Pharmacol Ther 27: 478–485
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Behne, M., Bremerich, D., Heinrich, J. et al. Respiratory effects and tolerability of Mr 2264 Cl. Eur J Clin Pharmacol 46, 301–304 (1994). https://doi.org/10.1007/BF00194395
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00194395